Advertisement

Inferior prognosis in poor mobilizing myeloma patients

  • Tuğçe Nur Yiğenoğlu
    Affiliations
    Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey
    Search for articles by this author
  • Semih Başcı
    Correspondence
    Corresponding author at: Department of Hematology and Stem Cell Transplantation Clinic, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, 06200, Yenimahalle, Ankara, Turkey.
    Affiliations
    Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey
    Search for articles by this author
  • Bahar Uncu Ulu
    Affiliations
    Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey
    Search for articles by this author
  • Mehmet Bakırtaş
    Affiliations
    Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey
    Search for articles by this author
  • Ali Kılınç
    Affiliations
    Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey
    Search for articles by this author
  • Derya Şahin
    Affiliations
    Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey
    Search for articles by this author
  • Tahir Darçın
    Affiliations
    Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey
    Search for articles by this author
  • Jale Yıldız
    Affiliations
    Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey
    Search for articles by this author
  • Nuran Ahu Baysal
    Affiliations
    Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey
    Search for articles by this author
  • Dicle İskender
    Affiliations
    Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey
    Search for articles by this author
  • Merih Kızıl Çakar
    Affiliations
    Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey
    Search for articles by this author
  • Mehmet Sinan Dal
    Affiliations
    Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey
    Search for articles by this author
  • Tuba Hacıbekiroğlu
    Affiliations
    Department of Hematology, Sakarya University Medical Faculty, Sakarya, Turkey
    Search for articles by this author
  • Fevzi Altuntaş
    Affiliations
    Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey
    Search for articles by this author
Published:January 09, 2020DOI:https://doi.org/10.1016/j.transci.2020.102722

      Abstract

      Introduction

      Induction treatment followed by autologous stem cell transplantation (ASCT) has been accepted as the standard treatment for multiple myeloma (MM) patients. Granulocyte colony stimulating agent (G-CSF), chemotherapy or agents likes plerixafor are being used for the mobilization of stem cells from bone marrow. In this study, we evaluated the impact of the mobilization methods on the outcome of MM patients after ASCT.

      Method

      The data of 205 MM patients who underwent ASCT at our center between December 2009 and January 2019 were retrospectively analyzed. Patients were divided into 2 groups as good mobilizers (patients who were mobilized with G-CSF alone) and poor mobilizers (patients who were failed to mobilize with G-CSF alone and mobilized with G-CSF + cylophosphomide or G-CSF + plerixafor).

      Results

      The median progression free survival (PFS) was 18.27 ± 3.22 months in good mobilizers and 14.22 ± 3.7 months in poor mobilizers. In G-CSF + cyclophosphamide method median PFS was 15.4 ± 4.9 months wheras it was only 4 months in G-CSF + plerixafor method. We did not find a statistically significant difference between good and poor mobilizers regarding median PFS (p: 0.342). The median overall survival (OS) was found 34.48 ± 4.2 months in good mobilizers and 15.13 ± 5.78 months in poor mobilizers. In G-CSF + cyclophosphamide method median OS was 17 ± 14.01 months wheras it was 10.66 ± 7.68 months in G-CSF + plerixafor method. We found a statistically significant difference between good and poor mobilizers regarding median OS (p: 0.007*).

      Conclusion

      Our study shows that difficulty in stem cell mobilization is correlated with worse outcome.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Attal M.
        • Harousseau J.L.
        • Stoppa A.M.
        • Sotto J.J.
        • Fuzibet J.G.
        • Rossi J.F.
        • et al.
        A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome.
        N Engl J Med. 1996; 335: 91-97
        • Child J.A.
        • Morgan G.J.
        • Davies F.E.
        • Owen R.G.
        • Bell S.E.
        • Hawkins K.
        • et al.
        High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
        N Engl J Med. 2003; 348: 1875-1883
        • Palumbo A.
        • Cavallo F.
        • Gay F.
        • Di Raimondo F.
        • Ben Yehuda D.
        • Petrucci M.T.
        • et al.
        Autologous transplantation and maintenance therapy in multiple myeloma.
        N Engl J Med. 2014; 371: 895-905
        • Gay F.
        • Oliva S.
        • Petrucci M.T.
        • Conticello C.
        • Catalano L.
        • Corradini P.
        • et al.
        Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
        Lancet Oncol. 2015; 16: 1617-1629
        • Attal M.
        • Lauwers-Cances V.
        • Hulin C.
        • Leleu X.
        • Caillot D.
        • Escoffre M.
        • et al.
        Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma.
        N Engl J Med. 2017; 376: 1311-1320
        • Gay F.
        • Oliva S.
        • Petrucci M.T.
        • Montefusco V.
        • Conticello C.
        • Musto P.
        • et al.
        Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis.
        Leukemia. 2017; 31: 1727-1734
        • Schulz C.
        • von Andrian U.H.
        • Massberg S.
        Hematopoietic stem and progenitor cells: their mobilization and homing to bone marrow and peripheral tissue.
        Immunol Res. 2009; 44: 160-168
        • Reddy R.L.
        Mobilization and collection of peripheral blood progenitor cells for transplantation.
        Transfus Apher Sci. 2005; 32: 63-72
        • Bensinger W.
        • DiPersio J.F.
        • McCarty J.M.
        Improving stem cell mobilization strategies: future directions.
        Bone Marrow Transplant. 2009; 43: 181-195
        • Bonig H.
        • Papayannopoulou T.
        Mobilization of hematopoieticstem/progenitor cells: general principles and molecular mechanisms.
        Methods Mol Biol. 2012; 904: 1-14
        • To L.B.
        • Haylock D.N.
        • Simmons P.J.
        • Juttner C.A.
        The biology and clinical uses of blood stem cells.
        Blood. 1997; 89: 2233-2258
        • Alvarez P.
        • Carrillo E.
        • Velez C.
        • Hita-Contreras F.
        • Martínez-Amat A.
        • Rodríguez-Serrano F.
        • et al.
        Regulatory systems in bone marrow for hematopoietic stem/progenitor cells mobilization and homing.
        Biomed Res Int. 2013; 2013312656
        • Angelopoulou M.K.
        • Tsirkinidis P.
        • Boutsikas G.
        • Vassilakopoulos T.P.
        • Tsirigotis P.
        • et al.
        New insights in the mobilization of hematopoietic stem cells in lymphoma and multiple myeloma patients.
        Biomed Res Int. 2014; 2014835138
        • Clercq E.
        The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil).
        Biochem Pharmacol. 2009; 77: 1655-1664
        • Brave M.
        • Farrell A.
        • Lin S.C.
        • Ocheltree T.
        • Pope Miksinski S.
        • Lee S.L.
        • et al.
        FDA review summary: mozobil in combination with granulocyte colony-timulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation.
        Oncology. 2010; 78: 282-288
        • Dingli D.
        • Nowakowski G.S.
        • Dispenzieri A.
        • Lacy M.Q.
        • Hayman S.
        • Litzow M.R.
        • et al.
        Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma.
        Clin Lymphoma Myeloma. 2006; 6: 384-388
        • DiPersio J.F.
        • Stadtmauer E.A.
        • Nademanee A.
        • Micallef I.N.
        • Stiff P.J.
        • Kaufman J.L.
        • et al.
        Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.
        Blood. 2009; 113: 5720-5726
        • Porrata L.F.
        • Gertz M.A.
        • Inwards D.J.
        • Litzow M.R.
        • Lacy M.Q.
        • Tefferi A.
        • et al.
        Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma.
        Blood. 2001; 98: 579-585
        • Brioli A.
        • Perrone G.
        • Patriarca F.
        • Pezzi A.
        • Nobile F.
        • Ballerini F.
        • et al.
        Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation.
        Bone Marrow Transpl. 2015; 50: 673-678
        • Morris C.
        • Chabannon C.
        • Masszi T.
        • Russell N.
        • Nahi H.
        • Kobbe G.
        • et al.
        Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor.
        Bone Marrow Transplant. 2019; https://doi.org/10.1038/s41409-019-0676-0
        • Moreb J.
        • Byrne M.
        • Shugarman I.
        • Zou F.
        • Xiong S.
        • May W.S.
        • et al.
        Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation.
        J Clin Apher. 2017; : 1-9
        • Durie B.G.
        • Harousseau J.L.
        • Miguel J.S.
        • Bladé J.
        • Barlogie B.
        • Anderson K.
        • et al.
        International uniform response criteria for multiple myeloma.
        Leukemia. 2006; 20: 1467-1473
        • Rihn C.
        • Cilley J.
        • Naik P.
        • Pedicano A.V.
        • Mehta J.
        Definition of myeloid engraftment after allogeneic hematopoietic stem cell transplantation.
        Haematologica. 2004; 89: 763-764
        • Giralt S.
        • Costa L.
        • Schriber J.
        • Dipersio J.
        • Maziarz R.
        • McCarty J.
        • et al.
        Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.
        Biol Blood Marrow Transplant. 2014; 20: 295-308
        • Arora M.
        • Burns L.J.
        • Barker J.N.
        • Miller J.S.
        • Defor T.E.
        • Olujohungbe A.B.
        • et al.
        Randomized comparison of granulocyte colony-stimulating factor versus granulocyte macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
        Biol Blood MarrowTransplant. 2004; 10: 395-404
        • Jantunen E.
        • Kvalheim G.
        Mobilization strategies inhard-to-mobilize patients with lymphoid malignancies.
        Eur J Haematol. 2010; 85: 463-471
        • Garfall A.
        • Dougherty A.
        • Vogl D.
        • Weiss B.M.
        • Cohen A.D.
        • Mick R.
        • et al.
        Association between mobilization regimen and progression-free survival after autologous stem cell transplantation for multiple myeloma.
        Bone Marrow Transplant. 2014; 49: 1439-1441
        • DiPersio J.F.
        • Micallef I.N.
        • Stiff P.J.
        • Bolwell B.J.
        • Maziarz R.T.
        • Jacobsen E.
        • et al.
        Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma.
        J Clin Oncol. 2009; 27: 4767-4773
        • Russell N.
        • Douglas K.
        • Ho A.
        • Mohty M.
        • Carlson K.
        • Ossenkoppele G.J.
        • et al.
        Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.
        Haematologica. 2013; 98
        • Alsayed Y.
        • Ngo H.
        • Runnels J.
        • Leleu X.
        • Singha U.K.
        • Pitsillides C.M.
        • et al.
        Mechanisms of regulation of CXCR4/ SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.
        Blood. 2007; 109: 2708-2717